menu
    • menu
    [{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Rheumatology","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"ARO-XDH","moa":"Xanthine dehydrogenase","graph1":"Rheumatology","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Preclinical","graph3":"GRO Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"GRO Biosciences \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"GRO Biosciences \/ Atlas Venture"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"HemoShear Therapeutics \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear Therapeutics \/ Horizon Therapeutics"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GRO Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            GRO Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rheumatology

                            Study Phase : Preclinical

                            Sponsor : Atlas Venture

                            Deal Size : $60.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            GRO Bio gathers $60M series B to take gout rival to Krystexxa into clinic

                            Details : The Proceeds from the financing will be used to advance the Company’s lead program ProGly-Uricase into the clinic for the treatment of refractory gout and to broaden the GRObio pipeline.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 19, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Preclinical

                            Sponsor : Atlas Venture

                            Deal Size : $60.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HemoShear Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            HemoShear Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rheumatology

                            Study Phase : Preclinical

                            Sponsor : Amgen Inc

                            Deal Size : $500.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

                            Details : Under the terms of the agreement Horizon received exclusive access to HemoShear's proprietary disease modeling REVEAL-TxTM drug discovery platform to discover new therapeutics for gout.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 21, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Preclinical

                            Sponsor : Amgen Inc

                            Deal Size : $500.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARO-XDH

                            Therapeutic Area : Rheumatology

                            Study Phase : Preclinical

                            Sponsor : Amgen Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arrowhead and Horizon Collaborate to Develop RNAi Therapeutic

                            Details : Arrowhead will conduct all activities through preclinical stages of development of the siRNA therapeutic, ARO-XDH. Horizon will receive a worldwide exclusive license to ARO-XDH and will be wholly responsible for clinical development and commercialization...

                            Product Name : ARO-XDH

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            June 21, 2021

                            Lead Product(s) : ARO-XDH

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Preclinical

                            Sponsor : Amgen Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Enzychem Lifesciences Corporation

                            South Korea arrow
                            CPhI India
                            Not Confirmed

                            Enzychem Lifesciences Corporation

                            South Korea arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mosedipimod

                            Therapeutic Area : Rheumatology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enzychem Lifesciences Announces Publication of Preclinical Study of EC-18 in Gouty Arthritis in Frontiers in I...

                            Details : The publication reports results from a study, examining a mitigating effect of PLAG on gouty inflammation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 01, 2020

                            Lead Product(s) : Mosedipimod

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth